Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 60 entries
Sorted by: Best Match Show Resources per page
Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease.

EBioMedicine

Tampe B, Tampe D, Zeisberg EM, Müller GA, Bechtel-Walz W, Koziolek M, Kalluri R, Zeisberg M.
PMID: 25717475
EBioMedicine. 2015 Jan;2(1):19-36. doi: 10.1016/j.ebiom.2014.11.005.

Progression of chronic kidney disease remains a principal problem in clinical nephrology and there is a pressing need for novel therapeutics and biomarkers. Aberrant promoter CpG island methylation and subsequent transcriptional silencing of specific genes have emerged as contributors...

Cite
Tampe B, Tampe D, Zeisberg EM, et al. Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease. EBioMedicine. 2015;2(1):19-36doi: 10.1016/j.ebiom.2014.11.005.
Tampe, B., Tampe, D., Zeisberg, E. M., Müller, G. A., Bechtel-Walz, W., Koziolek, M., Kalluri, R., & Zeisberg, M. (2015). Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease. EBioMedicine, 2(1), 19-36. https://doi.org/10.1016/j.ebiom.2014.11.005
Tampe, Björn, et al. "Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease." EBioMedicine vol. 2,1 (2015): 19-36. doi: https://doi.org/10.1016/j.ebiom.2014.11.005
Tampe B, Tampe D, Zeisberg EM, Müller GA, Bechtel-Walz W, Koziolek M, Kalluri R, Zeisberg M. Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease. EBioMedicine. 2015 Jan;2(1):19-36. doi: 10.1016/j.ebiom.2014.11.005. PMID: 25717475; PMCID: PMC4337426.
Copy Download .nbib Format: NLM
Quantitative characterization of higher-order mode converters in weakly multimoded fibers.

Optics express

Skorobogatiy M, Anastassiou C, Johnson S, Weisberg O, Engeness T, Jacobs S, Ahmad R, Fink Y.
PMID: 19471403
Opt Express. 2003 Nov 03;11(22):2838-47. doi: 10.1364/oe.11.002838.

We present a rigorous analysis methodology of fundamental to higher order mode converters in step index few mode optical fibers. We demonstrate experimental conversion from a fundamental LP01 mode to the higher order LP11 mode utilizing a multiple mechanical...

Cite
Skorobogatiy M, Anastassiou C, Johnson S, et al. Quantitative characterization of higher-order mode converters in weakly multimoded fibers. Opt Express. 2003;11(22):2838-47doi: 10.1364/oe.11.002838.
Skorobogatiy, M., Anastassiou, C., Johnson, S., Weisberg, O., Engeness, T., Jacobs, S., Ahmad, R., & Fink, Y. (2003). Quantitative characterization of higher-order mode converters in weakly multimoded fibers. Optics express, 11(22), 2838-47. https://doi.org/10.1364/oe.11.002838
Skorobogatiy, M, et al. "Quantitative characterization of higher-order mode converters in weakly multimoded fibers." Optics express vol. 11,22 (2003): 2838-47. doi: https://doi.org/10.1364/oe.11.002838
Skorobogatiy M, Anastassiou C, Johnson S, Weisberg O, Engeness T, Jacobs S, Ahmad R, Fink Y. Quantitative characterization of higher-order mode converters in weakly multimoded fibers. Opt Express. 2003 Nov 03;11(22):2838-47. doi: 10.1364/oe.11.002838. PMID: 19471403.
Copy Download .nbib Format: NLM
They wrote the book on fixing the system. Interview by Patrick Mullen.

Managed care (Langhorne, Pa.)

Porter ME, Teisberg EO.
PMID: 16749520
Manag Care. 2006 May;15(5):48-51.

No abstract available.

Cite
Porter ME, Teisberg EO. They wrote the book on fixing the system. Interview by Patrick Mullen. Manag Care. 2006;15(5):48-51
Porter, M. E., & Teisberg, E. O. (2006). They wrote the book on fixing the system. Interview by Patrick Mullen. Managed care (Langhorne, Pa.), 15(5), 48-51.
Porter, Michael E, and Teisberg, Elizabeth Olmsted. "They wrote the book on fixing the system. Interview by Patrick Mullen." Managed care (Langhorne, Pa.) vol. 15,5 (2006): 48-51.
Porter ME, Teisberg EO. They wrote the book on fixing the system. Interview by Patrick Mullen. Manag Care. 2006 May;15(5):48-51. PMID: 16749520.
Copy Download .nbib Format: NLM
A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma.

Journal of asthma and allergy

Chetty A, Sharda A, Warburton R, Weinberg EO, Dong J, Fang M, Sahagian GG, Chen T, Xue C, Castellot JJ, Haydon PG, Nielsen HC.
PMID: 30122959
J Asthma Allergy. 2018 Aug 01;11:159-171. doi: 10.2147/JAA.S151849. eCollection 2018.

BACKGROUND: Purinergic receptors control cell proliferation, apoptosis, migration, inflammation, and cytokine secretion. Increased expression of specific purinergic receptors is reported in asthma. The role of purinergic P2Y6 receptors (P2Y6R) in asthma is controversial.HYPOTHESIS: P2Y6R activation in asthma improves pulmonary...

Cite
Chetty A, Sharda A, Warburton R, et al. A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma. J Asthma Allergy. 2018;11:159-171doi: 10.2147/JAA.S151849.
Chetty, A., Sharda, A., Warburton, R., Weinberg, E. O., Dong, J., Fang, M., Sahagian, G. G., Chen, T., Xue, C., Castellot, J. J., Haydon, P. G., & Nielsen, H. C. (2018). A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma. Journal of asthma and allergy, 11159-171. https://doi.org/10.2147/JAA.S151849
Chetty, Anne, et al. "A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma." Journal of asthma and allergy vol. 11 (2018): 159-171. doi: https://doi.org/10.2147/JAA.S151849
Chetty A, Sharda A, Warburton R, Weinberg EO, Dong J, Fang M, Sahagian GG, Chen T, Xue C, Castellot JJ, Haydon PG, Nielsen HC. A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma. J Asthma Allergy. 2018 Aug 01;11:159-171. doi: 10.2147/JAA.S151849. eCollection 2018. PMID: 30122959; PMCID: PMC6078081.
Copy Download .nbib Format: NLM
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

Oncotarget

Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD.
PMID: 28881711
Oncotarget. 2017 Jul 06;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 08.

Oncogenic FLT3 kinase is a clinically validated target in acute myeloid leukemia (AML), and both multi-targeted and selective FLT3 inhibitors have been developed. Spleen tyrosine kinase (SYK) has been shown to be activated and increased in FLT3-ITD-positive AML patients,...

Cite
Weisberg EL, Puissant A, Stone R, et al. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017;8(32):52026-52044doi: 10.18632/oncotarget.19036.
Weisberg, E. L., Puissant, A., Stone, R., Sattler, M., Buhrlage, S. J., Yang, J., Manley, P. W., Meng, C., Buonopane, M., Daley, J. F., Lazo, S., Wright, R., Weinstock, D. M., Christie, A. L., Stegmaier, K., & Griffin, J. D. (2017). Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget, 8(32), 52026-52044. https://doi.org/10.18632/oncotarget.19036
Weisberg, Ellen L, et al. "Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase." Oncotarget vol. 8,32 (2017): 52026-52044. doi: https://doi.org/10.18632/oncotarget.19036
Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 08. PMID: 28881711; PMCID: PMC5581010.
Copy Download .nbib Format: NLM
Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies.

Fibrogenesis & tissue repair

Zeisberg M, Zeisberg EM.
PMID: 26330891
Fibrogenesis Tissue Repair. 2015 Sep 01;8:16. doi: 10.1186/s13069-015-0033-x. eCollection 2015.

Based on extensive pre-clinical achievements over the past decades, it appears to be due time for a successful clinical translation in the renal fibrosis field-but what is the quickest road to get there? In light of the recent launch...

Cite
Zeisberg M, Zeisberg EM. Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies. Fibrogenesis Tissue Repair. 2015;8:16doi: 10.1186/s13069-015-0033-x.
Zeisberg, M., & Zeisberg, E. M. (2015). Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies. Fibrogenesis & tissue repair, 816. https://doi.org/10.1186/s13069-015-0033-x
Zeisberg, Michael, and Zeisberg, Elisabeth M. "Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies." Fibrogenesis & tissue repair vol. 8 (2015): 16. doi: https://doi.org/10.1186/s13069-015-0033-x
Zeisberg M, Zeisberg EM. Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies. Fibrogenesis Tissue Repair. 2015 Sep 01;8:16. doi: 10.1186/s13069-015-0033-x. eCollection 2015. PMID: 26330891; PMCID: PMC4556008.
Copy Download .nbib Format: NLM
Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia.

Signal transduction and targeted therapy

Hu C, Zou F, Wang A, Miao W, Liang Q, Weisberg EL, Wang Y, Liu J, Wang W, Liu Q.
PMID: 34521806
Signal Transduct Target Ther. 2021 Sep 15;6(1):334. doi: 10.1038/s41392-021-00672-7.

No abstract available.

Cite
Hu C, Zou F, Wang A, et al. Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. Signal Transduct Target Ther. 2021;6(1):334doi: 10.1038/s41392-021-00672-7.
Hu, C., Zou, F., Wang, A., Miao, W., Liang, Q., Weisberg, E. L., Wang, Y., Liu, J., Wang, W., & Liu, Q. (2021). Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. Signal transduction and targeted therapy, 6(1), 334. https://doi.org/10.1038/s41392-021-00672-7
Hu, Chen, et al. "Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia." Signal transduction and targeted therapy vol. 6,1 (2021): 334. doi: https://doi.org/10.1038/s41392-021-00672-7
Hu C, Zou F, Wang A, Miao W, Liang Q, Weisberg EL, Wang Y, Liu J, Wang W, Liu Q. Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. Signal Transduct Target Ther. 2021 Sep 15;6(1):334. doi: 10.1038/s41392-021-00672-7. PMID: 34521806; PMCID: PMC8440619.
Copy Download .nbib Format: NLM
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.

Genes & cancer

Weisberg E, Roesel J, Furet P, Bold G, Imbach P, Flörsheimer A, Caravatti G, Jiang J, Manley P, Ray A, Griffin JD.
PMID: 21779428
Genes Cancer. 2010 Oct;1(10):1021-32. doi: 10.1177/1947601910396505.

Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clinical trials....

Cite
Weisberg E, Roesel J, Furet P, et al. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010;1(10):1021-32doi: 10.1177/1947601910396505.
Weisberg, E., Roesel, J., Furet, P., Bold, G., Imbach, P., Flörsheimer, A., Caravatti, G., Jiang, J., Manley, P., Ray, A., & Griffin, J. D. (2010). Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes & cancer, 1(10), 1021-32. https://doi.org/10.1177/1947601910396505
Weisberg, Ellen, et al. "Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison." Genes & cancer vol. 1,10 (2010): 1021-32. doi: https://doi.org/10.1177/1947601910396505
Weisberg E, Roesel J, Furet P, Bold G, Imbach P, Flörsheimer A, Caravatti G, Jiang J, Manley P, Ray A, Griffin JD. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010 Oct;1(10):1021-32. doi: 10.1177/1947601910396505. PMID: 21779428; PMCID: PMC3092267.
Copy Download .nbib Format: NLM
Not Only for Career Networking: Can LinkedIn Be Used for Radiology Education?.

Current problems in diagnostic radiology

Kauffman L, Weisberg EM, Fishman EK.
PMID: 34210558
Curr Probl Diagn Radiol. 2021 Jun 06; doi: 10.1067/j.cpradiol.2021.05.004. Epub 2021 Jun 06.

LinkedIn was a social media pioneer website initially focused on improving how professionals conduct business on the Internet. Since its acquisition by Microsoft, it has grown into one of the world's most influential social media platforms and become a...

Cite
Kauffman L, Weisberg EM, Fishman EK. Not Only for Career Networking: Can LinkedIn Be Used for Radiology Education?. Curr Probl Diagn Radiol. 2021;doi: 10.1067/j.cpradiol.2021.05.004.
Kauffman, L., Weisberg, E. M., & Fishman, E. K. (2021). Not Only for Career Networking: Can LinkedIn Be Used for Radiology Education?. Current problems in diagnostic radiology, . https://doi.org/10.1067/j.cpradiol.2021.05.004
Kauffman, Lilly, et al. "Not Only for Career Networking: Can LinkedIn Be Used for Radiology Education?." Current problems in diagnostic radiology vol. (2021). doi: https://doi.org/10.1067/j.cpradiol.2021.05.004
Kauffman L, Weisberg EM, Fishman EK. Not Only for Career Networking: Can LinkedIn Be Used for Radiology Education?. Curr Probl Diagn Radiol. 2021 Jun 06; doi: 10.1067/j.cpradiol.2021.05.004. Epub 2021 Jun 06. PMID: 34210558.
Copy Download .nbib Format: NLM
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

Leukemia

Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD.
PMID: 32144400
Leukemia. 2020 Sep;34(9):2543. doi: 10.1038/s41375-020-0782-4.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Weisberg E, Meng C, Case A, et al. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020;34(9):2543doi: 10.1038/s41375-020-0782-4.
Weisberg, E., Meng, C., Case, A., Sattler, M., Tiv, H. L., Gokhale, P. C., Buhrlage, S., Wang, J., Gray, N., Stone, R., Liu, S., Bhagwat, S. V., Tiu, R. V., Adamia, S., & Griffin, J. D. (2020). Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia, 34(9), 2543. https://doi.org/10.1038/s41375-020-0782-4
Weisberg, Ellen, et al. "Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia." Leukemia vol. 34,9 (2020): 2543. doi: https://doi.org/10.1038/s41375-020-0782-4
Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep;34(9):2543. doi: 10.1038/s41375-020-0782-4. PMID: 32144400.
Copy Download .nbib Format: NLM
#RadEd: How and Why to Use Twitter for Online Radiology Education.

Current problems in diagnostic radiology

Kauffman L, Weisberg EM, Zember WF, Fishman EK.
PMID: 33637393
Curr Probl Diagn Radiol. 2021 May-Jun;50(3):369-373. doi: 10.1067/j.cpradiol.2021.02.002. Epub 2021 Feb 10.

PURPOSE: As a digital presence rapidly becomes more important for educators, Twitter continues to emerge as a compelling source for publishing educational content. The social media platform has also evolved into a popular source for medical and radiology education....

Cite
Kauffman L, Weisberg EM, Zember WF, et al. #RadEd: How and Why to Use Twitter for Online Radiology Education. Curr Probl Diagn Radiol. 2021;50(3):369-373doi: 10.1067/j.cpradiol.2021.02.002.
Kauffman, L., Weisberg, E. M., Zember, W. F., & Fishman, E. K. (2021). #RadEd: How and Why to Use Twitter for Online Radiology Education. Current problems in diagnostic radiology, 50(3), 369-373. https://doi.org/10.1067/j.cpradiol.2021.02.002
Kauffman, Lilly, et al. "#RadEd: How and Why to Use Twitter for Online Radiology Education." Current problems in diagnostic radiology vol. 50,3 (2021): 369-373. doi: https://doi.org/10.1067/j.cpradiol.2021.02.002
Kauffman L, Weisberg EM, Zember WF, Fishman EK. #RadEd: How and Why to Use Twitter for Online Radiology Education. Curr Probl Diagn Radiol. 2021 May-Jun;50(3):369-373. doi: 10.1067/j.cpradiol.2021.02.002. Epub 2021 Feb 10. PMID: 33637393.
Copy Download .nbib Format: NLM
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.

Oncotarget

Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD.
PMID: 29299123
Oncotarget. 2017 Nov 06;8(66):109973-109984. doi: 10.18632/oncotarget.22409. eCollection 2017 Dec 15.

Resistance to targeted tyrosine kinase inhibitors (TKI) remains a challenge for the treatment of myeloid leukemias. Following treatment with TKIs, the bone marrow microenvironment has been found to harbor a small pool of surviving leukemic CD34+ progenitor cells. The...

Cite
Weisberg EL, Sattler M, Azab AK, et al. Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017;8(66):109973-109984doi: 10.18632/oncotarget.22409.
Weisberg, E. L., Sattler, M., Azab, A. K., Eulberg, D., Kruschinski, A., Manley, P. W., Stone, R., & Griffin, J. D. (2017). Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget, 8(66), 109973-109984. https://doi.org/10.18632/oncotarget.22409
Weisberg, Ellen L, et al. "Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition." Oncotarget vol. 8,66 (2017): 109973-109984. doi: https://doi.org/10.18632/oncotarget.22409
Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD. Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Nov 06;8(66):109973-109984. doi: 10.18632/oncotarget.22409. eCollection 2017 Dec 15. PMID: 29299123; PMCID: PMC5746358.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 60 entries